BeyondSpring (BYSI)
(Delayed Data from NSDQ)
$1.89 USD
+0.02 (1.07%)
Updated Aug 13, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BeyondSpring Inc. [BYSI]
Reports for Purchase
Showing records 21 - 40 ( 67 total )
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
We See Smooth Sailing for Plinabulin in CIN with FDA; Priority Review Granted, Breakthrough Designation Already in Hand
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Project Plinabulin Approval, But Launch, Financial, and Clinical Risk Remain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Sea Change in Risk Profile; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Plinabulin Answers the Breakthrough Designation Call; Target Adjusted to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Plinabulin Profile Rewarded with Breakthrough Therapy Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2Q Results; The Pins Are Set up; Plinabulin Has Started to Knock ''em Down
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Not a Bad Monday at All; PROTECTIVE-2 Planned Interim Hits Primary and Secondaries; Target Upped to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Updated Phase 2 Data Further Strengthen Plinabulin''s Profile; Dose and Regimen Compliance Improved
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; NDA Submissions and Upcoming Pivotal Data on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Pioneering Effort Continues; FDA Agrees to Change Focusing on Superiority of Plinabulin
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Rolling NDA Begins in China as Expected; Target Adjusted to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Endgame Starting Soon; Plinabulin Market Differentiation Important
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Study 106 Finally Gets Going to Potentially Broaden Scope of Plinabulin in CIN Significantly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; Data and Filings Approaching Quickly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Awaiting Data and NDAs; Target Reduced to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J